Results 31 to 40 of about 216,047 (309)

CCC-003 specifically suppresses ALK expression in ALK-mutated neuroblastoma cell lines.

open access: yes, 2021
(A) WST assay in ALK wild-type and ALK-mutated cells. SK-N-AS, SH-SY5Y and Kelly cells were incubated for 72 h after treatment with CCC-003 or mismatch polyamide.
Hiroki Nagase (734602)   +6 more
core   +1 more source

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome

open access: yesScientific Reports, 2021
The therapeutic potential of immune checkpoint inhibitors is currently being investigated in epithelial ovarian cancer (EOC), but immunological effects of the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis in EOC ...
Christine Bekos   +8 more
doaj   +1 more source

Presentación dosier: El trabajo de las maestras y la educación femenina en Argentina, Chile y Uruguay (1860-1960)

open access: yesDel Prudente Saber y el Máximo Posible de Sabor
Este dosier es resultado del I Workshop Internacional: las mujeres en las instituciones educativas, que organizaron las coordinadoras (Laura Graciela Rodríguez y María José Billorou) en la Facultad de Humanidades y Ciencias de la Educación de la ...
Laura Graciela Rodríguez   +1 more
doaj   +1 more source

“Inverted flap rhexis” – Salvation of intumescence

open access: yesIndian Journal of Ophthalmology
Intumescent cataract can be a challenge even for an experienced surgeon, particularly for creating a continuous curvilinear capsulorhexis (CCC) because of increased endolenticular pressure.
Reetesh K Singh, Aarti Popat
doaj   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

open access: yesMolecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain   +10 more
wiley   +1 more source

Identifying the need for specialized palliative care in adult cancer patients – development and validation of a screening procedure based on proxy assessment by physicians and filter questions

open access: yesBMC Cancer, 2019
Background One challenge in caring for cancer patients with incurable disease is the adequate identification of those in need for specialized palliative care (SPC). The study’s aim was to validate an easy to use phenomenological screening tool.
Christoph Ostgathe   +8 more
doaj   +1 more source

LIPIcs, Volume 137, CCC'19, Complete Volume

open access: yes, 2019
LIPIcs, Volume 137, CCC'19, Complete ...
Shpilka, Amir
core   +1 more source

CCC-003 suppresses tumor growth in human ALK-mutated neuroblastoma xenograft models.

open access: yes, 2021
(A, B, C) SH-SY5Y cells were subcutaneously injected into the flanks of female immune-deficient BALB/c nu/nu mice. Administration of CCC-003 began when the average tumor size reached 500 mm3. (A) The tumor volume of mice was measured twice a week.
Hiroki Nagase (734602)   +6 more
core   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

open access: yesMolecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington   +10 more
wiley   +1 more source

CCC-003 inhibits cell proliferation and ALK expression in ALK-mutated neuroblastoma cell lines to a greater extent than other ALK inhibitors.

open access: yes, 2021
(A, B, C) WST assay in ALK wild-type and ALK-mutated cells. (A) SK-N-AS cells were incubated for 72 h after treatment with CCC-003 or ALK inhibitors crizotinib and alectinib.
Hiroki Nagase (734602)   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy